Strategic Manufacturing Partnership Between Argent BioPharma and ECCPharm.

Argent BioPharma (ASX: RGT) has entered a strategic manufacturing partnership with ECCPharm Limited, an EU-GMP-certified pharmaceutical manufacturer. Under this agreement, ECCPharm will take over the full manufacturing and batch release of Argent’s key cannabinoid therapies, CannEpil and CogniCann. These therapies will be made available under early patient access programs in key European markets, including Ireland, the UK, and Germany. The transition of manufacturing from Argent’s European facilities to ECCPharm’s North Macedonian facility is expected to enhance efficiency while reducing operational costs for Argent. 

This collaboration allows Argent BioPharma to focus on clinical development, medical advancements, and regulatory expansion while ensuring a scalable and cost-effective production model. CannEpil targets refractory epilepsy, while CogniCann is being developed for neurodegenerative diseases, including Alzheimer’s and Parkinson’s. The partnership is expected to drive growth for both companies, securing a steady supply of high-quality cannabinoid-based therapies for patients in need.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com